Eli Lilly faces FDA crackdown for manufacturing issues at plant handling COVID-19 antibody: Reuters


Just days after Eli Lilly sent an COVID-19 antibody ahead for FDA scrutiny, the drugmaker’s immediate chances were halted by a damaging trial stop for the therapy. Now, the FDA has reportedly knocked Lilly for its manufacturing controls at a New Jersey site producing the antibody. 

The FDA knocked Lilly’s Branchburg, New Jersey, plant for deleting data on its manufacturing processes and for failing to properly audit the facility, sources told Reuters. The shortfalls could endanger an FDA emergency use authorization for the antibody. 

After an inspection in November, FDA investigators noted the quality control deficiencies in a letter to Lilly, Reuters reported, in what was likely a Form 483 detailing the flaws. The investigators’ findings qualified as official action indicated in the notice, the highest enforcement priority level from the FDA for its observations, Reuters said.

SPONSORED BY CBSET & CILCARE

White Paper: Why Test Your COVID-19 Therapies for Auditory Safety?

Repurposing approved compounds for COVID-19 can expedite regulatory review, but changing formulation, dosing, and administration route may add risks. Learn how preclinical ototoxicity assessment can help you avoid clinical and financial risks.

Spokespersons for neither the FDA nor Lilly could not be reached for comment by press time. 

Lilly’s Branchburg plant not only flopped its FDA inspection, but on-site workers had already warned company officials about the issues before the walk-through, according to Reuters sources. Those complaints reportedly centered on understaffing and falsified quality control records.  

The FDA citations at the plant weren’t related to LY-CoV555 production, and Lilly has drafted a remediation plan to address the agency’s concerns, the drugmaker told Reuters. 

RELATED: Another day, another delay: NIH halts phase 3 study of Lilly’s COVID-19 antibody

The FDA’s hammer drop comes as a one-two punch to Lilly’s chances at an emergency nod for LY-CoV555 after the National Institutes of Health (NIH) halted a late-stage trial for the antibody Tuesday.

The trial’s independent data safety monitoring board recommended the company pause enrollment, a Lilly spokesperson told CNBC in an email Tuesday, adding, “Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study.”

The news comes one day after Johnson & Johnson paused a phase 3 study for its COVID-19 vaccine because a patient had an “unexplained illness”—and about a month after AstraZeneca suspended a trial for its COVID-19 jab because a patient developed transverse myelitis, a type of spinal cord inflammation that can be triggered by infections.

It also comes just days after Lilly asked the FDA to clear LY-CoV555 for emergency use based on phase 2 data showing it cut the rate of hospitalizations in patients recently diagnosed with mild to moderate COVID-19. However, two of the three doses tested in the study failed to beat placebo in terms of reducing viral load by the 11-day mark.

RELATED: Amid Regeneron’s emergency use bid, former FDA chief says U.S. ‘too late’ on mass manufacture of COVID-19 antibodies

Lilly is one of two drugmakers chasing an emergency authorization for its COVID-19 antibody; Regeneron sent its antibody cocktail REGN-COV2 ahead for FDA scrutiny last week, after it was used to treat President Donald Trump.

Regeneron’s therapy comes with immense hype after Trump’s treatment. Since his release from Walter Reed Medical Center earlier this month, Trump has called the unapproved therapy a “cure,” though Regeneron CEO Len Schleifer, M.D., Ph.D., has said the drugmaker is still chasing large-scale clinical data to back  its use.

With either drug a potential winner with regulators, experts have warned the industry has not done enough to build manufacturing capacity for antibodies, which are expensive to produce and distribute. Sunday, former FDA Commissioner Scott Gottlieb. M.D., warned that drugmakers were “too late” to meet U.S. demand this year and would likely only start to keep up in 2021.



Source link

Scroll to Top